| Abstract | Fungating wounds sometimes occur in people with advanced cancer. Care usually aims to slow down disease progression and improve quality of life by relieving physical symptoms using appropriate dressings and other applied treatments.
There is weak evidence to suggest that patients with superficial fungating breast lesions (smaller than 1cm) who have received either previous radiotherapy, surgery, hormone therapy or chemotherapy for their breast cancer may extend the time to disease progression by receiving topical 6% miltefosine solution. There is insufficient evidence to direct practice with regard to improving quality of life or managing other wound symptoms associated with fungating wounds. |